

Point of Care/ Rapid Diagnostics Market by Product (Glucose, HIV, Hepatitis C, Pregnancy), Platform (Microfluidics, Dipstick, Immunoassay), Purchase(OTC, Prescription), Sample(Blood, Urine), User (Pharmacy, Hospital, Homecare) - Global Forecast to 2027

Market Report | 2022-12-08 | 383 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global point-of-care and rapid diagnostics market is projected to reach USD 75.5 Billion by 2027 from USD 45.4 Billion in 2022, at a CAGR of 10.7% during the forecast period. The growth in the point-of-care and rapid diagnostics market is majorly driven by the significant rising cases of infectious diseases, diabetes, cardiovascular diseases and cancer. Also, rapidly growing older population, and increasing research & funding initiatives by government to support the development and adoption of POC is anticipated to promote the growth of market. The rising number of CLIA waivers over the years indicates a favorable approval environment, which will encourage players to focus on the development of point-of-care diagnostic products

However, are a lack of alignment with test results obtained from laboratories and stringent and time-consuming approval policies are expected to restrain market growth in the coming years.

"The glucose monitoring device held the significant share of point-of-care and rapid diagnostics market during the forecast period.

Based on products, the point-of-care and rapid diagnostics market is segmented into glucose monitoring products, cardiometabolic monitoring products, COVID-19 testing products, infectious disease testing products, coagulation monitoring products, pregnancy & fertility testing products, hematology testing products, thyroid stimulating hormone testing products, tumor/cancer marker testing products, fecal occult testing products, urinalysis testing products, drug-of-abuse testing products,

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

cholesterol testing products, and other products.

The glucose monitoring device held the significant share of point-of-care and rapid diagnostics market during the forecast period. The rising diabetic patient population worldwide and growing awareness about the presence of self glucose monitoring and ongoing technological advancements are anticipated to play a critical role in propelling the growth of the segment.

"The Lateral Flow Assays segment accounted for the largest share of the point-of-care diagnostics market, by platform, in 2021"

Based on platform, the point-of-care and rapid diagnostics market is segmented into lateral flow assays, immunoassays, microfluidics, dipsticks, and molecular diagnostics. The lateral flow assays segment accounted for the largest share of the market in 2021. The growing adoption of lateral flow assays in point-of care testing facilities owing to the greater advantages offered by lateral flow assay by replacing conventional, lengthy laboratory procedures are likely to contribute towards the growth of this segment during the forecast period.

"The OTC Testing Products segment, by mode of purchase segment, accounted for the largest share of the global point-of-care and rapid diagnostics market in 2021"

On the basis of mode of purchase, the point-of-care and rapid diagnostics market is segmented into OTC testing products and prescription-based testing products. The OTC testing products segment accounted for the largest share of the market in 2021. Factors such as the rising prevalence of diabetes in developing countries where glucose monitors are available without a prescription, growing online purchase of OTC point-of-care products, increasing patient preference for OTC products for the diagnosis of pregnancy, lower cost of OTC products, and the increasing preference for self-monitoring are driving the growth of the OTC testing products market

"On the basis of sample, blood segment is accounted for the largest share of the global point-of-care and rapid diagnostics market in 2021"

On the basis of sample, the point-of-care and rapid diagnostics market is segmented into blood, urine, nasal and oropharyngeal swabs, and other samples. The blood sample segment accounted for the largest market share 2021. Factors such as the rising prevalence of HIV, diabetes, and malaria and the growing applications of blood samples for the diagnosis of various diseases are anticipated to boost the growth of this segment.

"On the basis of End Users, clinical laboratories segment accounted for the largest share of point-of-care and rapid diagnostics market in 2021"

On the basis of end users, the point-of-care and rapid diagnostics market is segmented into clinical laboratories; ambulatory care facilities and physicians' offices; pharmacies, retail clinics, and E-commerce platforms; hospitals, critical care centers, and urgent care centers; home care & self-testing; and other end users.

The clinical laboratories segment accounted for the largest share of point-of-care and rapid diagnostics market in 2021. The recent outbreak of COVID-19 positively impacted the clinical laboratories segment, as the pandemic has boosted clinical laboratory testing services. Based on the study published by the National Center for Biotechnology Information in July 2020, the use of clinical diagnostics, including molecular and serological testing approaches for severe acute respiratory syndrome?coronavirus 2 (SARS-CoV-2) testing, has increased. The increasing number of COVID-19 variants is further likely to drive the growth of the clinical laboratories segment. In February 2021, Thermo Fisher Scientific launched the Towpaths COVID-19 HT Kit for use on its automated amplitude platform to increase its COVID-19 testing capacity by combining Thermo Fisher's

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

extraction and real-time PCR instruments with liquid handling products from Tecan Group.

"The Asia Pacific market is expected to grow at the highest CAGR during the forecast period"

The global point-of-care and rapid diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2021, North America accounted for the largest share of this market, followed by Europe. The rising prevalence of lifestyle diseases in the region, growing number of rapid point-of-care products approvals, presence of well-established players, and government initiatives to support the wider adoption of rapid testing are some of the key factors driving the growth of the North American point-of-care and rapid diagnostics market.

On the other hand, the Asia Pacific market is projected to register the highest growth during the forecast period. This is attributed to the presence of densely populated countries in the region such as China and India; with increasing prevalence of target diseases, growing awareness of POCT products, emergence of new rapid diagnostic kits manufacturer, expansion of healthcare infrastructure, growing initiatives by government to promote the adoption of POCT, and increased focus of key players in establishing their foothold in Asian Countries.

A breakdown of the primary participants referred to for this report is provided below:

-□By Company Type: Tier 1-48%, Tier 2-36%, and Tier 3- 16%

-□By Designation: C-level-10%, Director-level-14%, and Others-76%

-□By Region: North America-40%, Europe-32%, Asia Pacific-20%, Latin America-5%, and the Middle East & Africa-3%

The major players operating in the point-of-care and rapid diagnostics market are Abbott (US), Becton, Dickinson and Company (US), Danaher Corporation (US), Siemens Healthineers AG (Germany), and F. Hoffman-La Roche Ltd. (Switzerland), Quidel Corporation (US), Chembio Diagnostics (US), EKF Diagnostics (UK), Trinity Biotech plc (Ireland), Nova Biomedical (US), PTS Diagnostics (US), Sekisui Diagnostics (US), Thermo Fisher Scientific (US), and bioMerieux SA (France).

Research Coverage

This report studies the point-of-care and rapid diagnostics market based on product, platform, mode of purchase, sample, end user and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.

This report provides insights on the following pointers:

?□Market Penetration: Comprehensive information on the product portfolios offered by the top players in the point-of-care diagnostics market

?□Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the point-of-care diagnostics market

?□Market Development: Comprehensive information on lucrative emerging regions

?□Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the point-of-care diagnostics market

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

?Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

Table of Contents:

1	INTRODUCTION	48
1.1	STUDY OBJECTIVES	48
1.2	MARKET DEFINITION	48
1.3	STUDY SCOPE	49
1.3.1	MARKETS COVERED	49
1.3.2	GEOGRAPHIC SCOPE	49
1.3.3	INCLUSIONS AND EXCLUSIONS	50
1.3.4	YEARS CONSIDERED	50
1.4	CURRENCY	51
1.5	STAKEHOLDERS	51
1.6	SUMMARY OF CHANGES	51
2	RESEARCH METHODOLOGY	53
2.1	RESEARCH DATA	53
FIGURE 1	RESEARCH DESIGN	53
2.1.1	SECONDARY RESEARCH	54
2.1.2	PRIMARY RESEARCH	55
2.1.2.1	Key data from primary sources	55
2.1.2.2	Key industry insights	56
FIGURE 2	BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS	56
FIGURE 3	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET: BREAKDOWN OF PRIMARIES	57
2.2	MARKET SIZE ESTIMATION	57
FIGURE 4	RESEARCH METHODOLOGY: HYPOTHESIS BUILDING	58
2.2.1	VENDOR REVENUE MAPPING-BASED MARKET ESTIMATION	58
2.2.2	END-USER ASSESSMENT-BASED MARKET ESTIMATION	59
FIGURE 5	MARKET SIZE ESTIMATION METHODOLOGY: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET	60
2.2.3	PRIMARY RESEARCH VALIDATION	60
2.3	DATA TRIANGULATION	61
FIGURE 6	DATA TRIANGULATION METHODOLOGY	61
2.4	RESEARCH ASSUMPTIONS AND LIMITATIONS	62
2.4.1	RESEARCH ASSUMPTIONS	62
2.4.2	RESEARCH LIMITATIONS	62
?		
3	EXECUTIVE SUMMARY	63
FIGURE 7	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)	63
FIGURE 8	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PLATFORM, 2022 VS. 2027 (USD MILLION)	64
FIGURE 9	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022 VS. 2027 (USD MILLION)	65
FIGURE 10	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)	65
FIGURE 11	GEOGRAPHICAL SNAPSHOT OF POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET	66
4	PREMIUM INSIGHTS	67
4.1	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET OVERVIEW	67
FIGURE 12	RIISING PREVALENCE OF TARGET DISEASES TO DRIVE MARKET	67
4.2	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)	68
FIGURE 13	GLUCOSE MONITORING PRODUCTS SEGMENT WILL DOMINATE MARKET IN 2027	68

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

4.3	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET SHARE, BY MODE OF PURCHASE (2022)	69
	FIGURE 14	OTC TESTING PRODUCTS SEGMENT TO ACCOUNT FOR LARGER MARKET SHARE IN 2022
4.4	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET SHARE, BY PLATFORM, 2022 VS. 2027	69
	FIGURE 15	LATERAL FLOW ASSAYS WILL CONTINUE TO DOMINATE MARKET IN 2027
4.5	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	70
	FIGURE 16	CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
5	MARKET OVERVIEW	71
5.1	INTRODUCTION	71
5.2	MARKET DYNAMICS	71
	FIGURE 17	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1	DRIVERS	72
5.2.1.1	High prevalence of infectious diseases	72
	FIGURE 18	HIV INFECTION, BY REGION, 2021
5.2.1.2	Increasing incidence of target conditions	73
5.2.1.3	Supportive government policies	73
5.2.1.4	Dearth of skilled laboratory technicians	74
5.2.1.5	Rising number of CLIA-waived POC tests	74
	TABLE 1	RECENT WAIVERS FOR PRODUCTS
	?	
5.2.2	RESTRAINTS	75
5.2.2.1	Pricing pressure owing to reimbursement cuts and budget constraints	75
5.2.2.2	Stringent regulatory policies	75
5.2.3	OPPORTUNITIES	76
5.2.3.1	Emerging markets	76
5.2.3.2	Healthcare decentralization	76
5.2.3.3	Increasing provider awareness about novel technologies	77
5.2.3.4	POC tests with multiplexing capabilities	77
5.2.3.5	Growing investments and funding for product development	78
5.2.4	CHALLENGES	78
5.2.4.1	Lack of alignment with definitive central lab methods	78
5.2.4.2	Inadequate adoption of POC devices in professional settings	79
5.2.4.3	Reluctance to change existing diagnostic practices	79
5.2.4.4	Premium pricing of novel platforms	79
5.3	TECHNOLOGY ANALYSIS: EMERGING POINT-OF-CARE APPLICATIONS	80
5.3.1	SEPSIS BIOMARKERS	80
5.3.2	STROKE/CARDIAC MARKERS	81
5.3.3	THYROID TESTING	81
5.3.4	DNA TESTING	81
5.3.5	ENDOCRINE TESTING	82
5.3.6	RESPIRATORY DIAGNOSTICS	82
5.4	REGULATORY LANDSCAPE	82
	TABLE 2	KEY REGULATORY BODIES AND GOVERNMENT AGENCIES
5.4.1	KEY REGULATORY GUIDELINES	83
5.4.1.1	US	83
	FIGURE 19	US: REGULATORY PROCESS FOR IVD DEVICES
5.4.1.2	Canada	84
	FIGURE 20	CANADA: REGULATORY PROCESS FOR IVD DEVICES

5.4.1.3 Europe 84

FIGURE 21 EUROPE: REGULATORY PROCESS FOR IVD DEVICES 85

5.4.1.4 Japan 86

FIGURE 22 JAPAN: REGULATORY PROCESS FOR IVD DEVICES 86

5.4.1.5 China 86

TABLE 3 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 87

5.4.1.6 India 87

FIGURE 23 INDIA: REGULATORY PROCESS FOR IVD DEVICES 87

5.4.1.7 Brazil 87

FIGURE 24 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES 88

5.5 VALUE CHAIN ANALYSIS 88

FIGURE 25 VALUE CHAIN ANALYSIS-MAXIMUM VALUE ADDED DURING REGULATION AND DISTRIBUTION STAGES 88
?

5.6 SUPPLY CHAIN ANALYSIS 89

5.6.1 PROMINENT COMPANIES 89

5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES 89

5.6.3 END USERS 90

FIGURE 26 SUPPLY CHAIN ANALYSIS 90

5.7 PRICING TREND ANALYSIS 90

TABLE 4 AVERAGE PRICE OF GLUCOSE MONITORING AND CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2021 (USD) 90

TABLE 5 AVERAGE PRICE OF INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2021 (USD) 91

TABLE 6 AVERAGE PRICE OF OTHER POINT-OF-CARE TESTING PRODUCTS, BY COUNTRY, 2021 (USD) 91

5.8 PORTER'S FIVE FORCES 92

5.8.1 OVERVIEW 92

TABLE 7 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS 92

5.8.2 BARGAINING POWER OF BUYERS 92

5.8.3 BARGAINING POWER OF SUPPLIERS 92

5.8.4 THREAT OF NEW ENTRANTS 92

5.8.5 THREAT OF SUBSTITUTES 93

5.8.6 INTENSITY OF COMPETITIVE RIVALRY 93

5.9 PATENT ANALYSIS 93

FIGURE 27 TOP 10 PATENT APPLICANTS FOR CARDIAC MARKER TESTING (JANUARY 2012-NOVEMBER 2022) 93

FIGURE 28 TOP 10 PATENT OWNERS FOR POINT-OF-CARE DIAGNOSTICS (JANUARY 2012-NOVEMBER 2022) 94

FIGURE 29 ECOSYSTEM COVERAGE: PARENT MARKET (IN VITRO DIAGNOSTICS) 94

5.10 KEY CONFERENCES AND EVENTS 95

TABLE 8 POINT-OF-CARE & RAPID DIAGNOSTICS MARKET: DETAILED LIST OF MAJOR CONFERENCES & EVENTS, 2021-2023 95

5.11 CASE STUDY 95

5.11.1 DEVELOPMENT OF HIGH-SENSITIVITY TROPONIN I 95

TABLE 9 CASE 1: DIAGNOSING LOWER LEVELS OF TROPONIN IN CARDIAC PATIENTS 95

FIGURE 30 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 96

5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 96

5.12.1 KEY STAKEHOLDERS 96

FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CARDIAC MARKER TESTING KITS AND INSTRUMENTS 96

TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PRODUCT SEGMENTS (%) 97

5.13 KEY BUYING CRITERIA 97

TABLE 11 KEY BUYING CRITERIA FOR PRODUCTS 97

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

?

6 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PRODUCT 98

6.1 INTRODUCTION 99

TABLE 12 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 99

6.2 GLUCOSE MONITORING PRODUCTS 100

TABLE 13 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020-2027 (USD MILLION) 100

TABLE 14 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY PLATFORM, 2020-2027 (USD MILLION) 101

TABLE 15 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY MODE OF PURCHASE, 2020-2027 (USD MILLION) 101

TABLE 16 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY END USER, 2020-2027 (USD MILLION) 102

TABLE 17 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY SAMPLE, 2020-2027 (USD MILLION) 102

TABLE 18 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY REGION, 2020-2027 (USD MILLION) 103

6.2.1 STRIPS 103

6.2.1.1 Strips make blood glucose testing easy and hassle-free 103

TABLE 19 GLUCOSE MONITORING STRIPS MARKET, BY REGION, 2020-2027 (USD MILLION) 103

6.2.2 METERS 104

6.2.2.1 Extremely helpful in monitoring blood glucose levels and adjusting therapeutic regimens 104

TABLE 20 GLUCOSE MONITORING METERS MARKET, BY REGION, 2020-2027 (USD MILLION) 104

6.2.3 LANCETS AND LANCING DEVICES 104

6.2.3.1 Lancets and lancing devices segment to register lower growth in glucose monitoring products market 104

TABLE 21 GLUCOSE MONITORING LANCETS AND LANCING DEVICES MARKET, BY REGION, 2020-2027 (USD MILLION) 105

6.3 COVID-19 TESTING PRODUCTS 105

6.3.1 COVID-19 PANDEMIC ACCELERATED DEMAND FOR POC/RAPID DIAGNOSTIC PRODUCTS 105

TABLE 22 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COVID-19 TESTING PRODUCTS, BY PLATFORM, 2020-2027 (USD MILLION) 106

TABLE 23 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COVID-19 TESTING PRODUCTS, BY MODE OF PURCHASE, 2020-2027 (USD MILLION) 106

TABLE 24 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COVID-19 TESTING PRODUCTS, BY END USER, 2020-2027 (USD MILLION) 107

TABLE 25 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COVID-19 TESTING PRODUCTS, BY SAMPLE, 2020-2027 (USD MILLION) 107

TABLE 26 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COVID-19 TESTING PRODUCTS, BY REGION, 2020-2027 (USD MILLION) 108

?

6.4 CARDIOMETABOLIC MONITORING PRODUCTS 108

TABLE 27 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020-2027 (USD MILLION) 108

TABLE 28 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY PLATFORM, 2020-2027 (USD MILLION) 109

TABLE 29 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY MODE OF PURCHASE, 2020-2027 (USD MILLION) 109

TABLE 30 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY END USER,

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2020-2027 (USD MILLION)□110

TABLE 31□POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY SAMPLE, 2020-2027 (USD MILLION)□110

TABLE 32□POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2020-2027 (USD MILLION)□111

6.4.1□BLOOD GAS/ELECTROLYTE TESTING PRODUCTS□111

6.4.1.1□Technological advancements in blood gas/electrolyte products to drive market□111

TABLE 33□POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY REGION, 2020-2027 (USD MILLION)□112

6.4.2□CARDIAC MARKER TESTING PRODUCTS□112

6.4.2.1□Rising prevalence of heart diseases and development of new POC test to support market growth□112

TABLE 34□POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY REGION, 2020-2027 (USD MILLION)□113

6.4.3□HBA1C TESTING PRODUCTS□113

6.4.3.1□Government initiatives promoting regular use of HbA1c testing□113

TABLE 35□POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY REGION, 2020-2027 (USD MILLION)□114

6.5□INFECTIOUS DISEASE TESTING PRODUCTS□115

TABLE 36□POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020-2027 (USD MILLION)□115

TABLE 37□POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY PLATFORM, 2020-2027 (USD MILLION)□116

TABLE 38□POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2020-2027 (USD MILLION)□116

TABLE 39□POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY END USER, 2020-2027 (USD MILLION)□117

TABLE 40□POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY SAMPLE, 2020-2027 (USD MILLION)□117

TABLE 41□POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2020-2027 (USD MILLION)□118

6.5.1□HIV TESTING PRODUCTS□118

6.5.1.1□Rising prevalence of HIV to drive market□118

TABLE 42□POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY MODE OF PURCHASE, 2020-2027 (USD MILLION)□118

TABLE 43□POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY END USER, 2020-2027 (USD MILLION)□119

TABLE 44□POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY SAMPLE, 2020-2027 (USD MILLION)□119

TABLE 45□POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY REGION, 2020-2027 (USD MILLION)□120

6.5.2□RESPIRATORY INFECTION TESTING PRODUCTS□120

6.5.2.1□POCT products for diagnosis of respiratory infections offer lower sensitivity□120

TABLE 46□POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY MODE OF PURCHASE, 2020-2027 (USD MILLION)□121

TABLE 47□POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY END USER, 2020-2027 (USD MILLION)□121

TABLE 48□POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR RESPIRATORY TESTING PRODUCTS, BY SAMPLE, 2020-2027 (USD

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

MILLION)122

TABLE 49POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION, 2020-2027 (USD MILLION)122

6.5.3HEPATITIS C TESTING PRODUCTS122

6.5.3.1Central and East Asia among highly affected regions by hepatitis C122

TABLE 50POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY MODE OF PURCHASE, 2020-2027 (USD MILLION)123

TABLE 51POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY END USER, 2020-2027 (USD MILLION)123

TABLE 52POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY SAMPLE, 2020-2027 (USD MILLION)124

TABLE 53POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY REGION, 2020-2027 (USD MILLION)124

6.5.4HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS124

6.5.4.1Rising prevalence of HAIs to drive market124

TABLE 54POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY MODE OF PURCHASE, 2020-2027 (USD MILLION)125

TABLE 55POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY END USER, 2020-2027 (USD MILLION)125

TABLE 56POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY SAMPLE, 2020-2027 (USD MILLION)126

TABLE 57POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY REGION, 2020-2027 (USD MILLION)126

6.5.5INFLUENZA TESTING PRODUCTS127

6.5.5.1Rising influenza prevalence to drive demand for influenza testing products127

TABLE 58POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY MODE OF PURCHASE, 2020-2027 (USD MILLION)127

TABLE 59POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY END USER, 2020-2027 (USD MILLION)128

TABLE 60POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY SAMPLE, 2020-2027 (USD MILLION)128

TABLE 61POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY REGION, 2020-2027 (USD MILLION)129

6.5.6TROPICAL DISEASE TESTING PRODUCTS129

6.5.6.1Increasing government funding for use of POC in tropical disease testing to support market growth129

TABLE 62POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2020-2027 (USD MILLION)130

TABLE 63POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY END USER, 2020-2027 (USD MILLION)130

TABLE 64POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR TROPICAL DISEASES PRODUCTS, BY SAMPLE, 2020-2027 (USD MILLION)131

TABLE 65POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY REGION, 2020-2027 (USD MILLION)131

6.5.7SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS131

TABLE 66POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS, BY TYPE, 2020-2027 (USD MILLION)132

TABLE 67POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS, BY MODE OF PURCHASE, 2020-2027 (USD MILLION)132

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 68	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS, BY END USER, 2020-2027 (USD MILLION)	133
TABLE 69	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS, BY SAMPLE, 2020-2027 (USD MILLION)	133
TABLE 70	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS, BY REGION, 2020-2027 (USD MILLION)	134
6.5.7.1	Syphilis testing products	134
6.5.7.1.1	Introduction of rapid tests for syphilis to support market growth	134
TABLE 71	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY REGION, 2020-2027 (USD MILLION)	135
6.5.7.2	Human papillomavirus (HPV) testing products	135
6.5.7.2.1	Technological advancements to aid market growth	135
TABLE 72	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY REGION, 2020-2027 (USD MILLION)	136
6.5.7.3	Chlamydia trachomatis testing products	136
6.5.7.3.1	Growing incidence of chlamydia and rising awareness among patients to drive market	136
TABLE 73	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY REGION, 2020-2027 (USD MILLION)	137
6.5.7.4	Herpes simplex virus (HSV) testing products	137
6.5.7.4.1	Increasing incidence of HSV to boost adoption of rapid tests	137
TABLE 74	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY REGION, 2020-2027 (USD MILLION)	137
6.5.8	TUBERCULOSIS (TB) TESTING PRODUCTS	138
6.5.8.1	Rising prevalence of TB and initiatives by governments to propel demand for rapid TB tests	138
TABLE 75	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR TB TESTING PRODUCTS, BY MODE OF PURCHASE, 2020-2027 (USD MILLION)	138
TABLE 76	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR TB TESTING PRODUCTS, BY END USER, 2020-2027 (USD MILLION)	139
TABLE 77	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR TB TESTING PRODUCTS, BY SAMPLE, 2020-2027 (USD MILLION)	139
TABLE 78	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR TB TESTING PRODUCTS, BY REGION, 2020-2027 (USD MILLION)	140
6.5.9	CLOSTRIDIUM DIFFICILE INFECTION (CDI) TESTING PRODUCTS	140
6.5.9.1	Increasing cases of CDI infections among hospitalized patients to support market growth	140
TABLE 79	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CDI TESTING PRODUCTS, BY MODE OF PURCHASE, 2020-2027 (USD MILLION)	140
TABLE 80	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CDI TESTING PRODUCTS, BY END USER, 2020-2027 (USD MILLION)	141
TABLE 81	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CDI TESTING PRODUCTS, BY SAMPLE, 2020-2027 (USD MILLION)	141
TABLE 82	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CDI TESTING PRODUCTS, BY REGION, 2020-2027 (USD MILLION)	142
6.5.10	OTHER INFECTIOUS DISEASE TESTING PRODUCTS	142
TABLE 83	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2020-2027 (USD MILLION)	142
TABLE 84	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY END USER, 2020-2027 (USD MILLION)	143

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 85	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY SAMPLE, 2020-2027 (USD MILLION)	143
TABLE 86	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2020-2027 (USD MILLION)	144
6.6	COAGULATION MONITORING PRODUCTS	144
TABLE 87	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020-2027 (USD MILLION)	145
TABLE 88	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY PLATFORM, 2020-2027 (USD MILLION)	145
TABLE 89	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY MODE OF PURCHASE, 2020-2027 (USD MILLION)	145
TABLE 90	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY END USER, 2020-2027 (USD MILLION)	146
TABLE 91	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY SAMPLE, 2020-2027 (USD MILLION)	146
TABLE 92	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY REGION, 2020-2027 (USD MILLION)	147
6.6.1	PT/INR TESTING PRODUCTS	147
6.6.1.1	Most commonly used coagulation monitoring method	147
TABLE 93	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY REGION, 2020-2027 (USD MILLION)	148
6.6.2	ACT/APTT TESTING PRODUCTS	148
6.6.2.1	Rising number of patients undergoing angioplasty and dialysis globally to support market growth	148
TABLE 94	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY REGION, 2020-2027 (USD MILLION)	148
6.7	PREGNANCY AND FERTILITY TESTING PRODUCTS	149
TABLE 95	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020-2027 (USD MILLION)	149
TABLE 96	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY PLATFORM, 2020-2027 (USD MILLION)	149
TABLE 97	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY MODE OF PURCHASE, 2020-2027 (USD MILLION)	150
TABLE 98	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY END USER, 2020-2027 (USD MILLION)	150
TABLE 99	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY SAMPLE, 2020-2027 (USD MILLION)	151
TABLE 100	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY REGION, 2020-2027 (USD MILLION)	151
6.7.1	PREGNANCY TESTING PRODUCTS	152
6.7.1.1	Rising inclination toward home testing to support market growth	152
TABLE 101	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY REGION, 2020-2027 (USD MILLION)	152
6.7.2	FERTILITY TESTING PRODUCTS	152
6.7.2.1	Increasing awareness of fertility testing to drive market	152
TABLE 102	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY REGION, 2020-2027 (USD MILLION)	153
6.8	TUMOR/CANCER MARKER TESTING PRODUCTS	153

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

6.8.1 INCREASING PREVALENCE OF CANCER TO BOOST DEMAND FOR RAPID TESTING 153

TABLE 103 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY PLATFORM, 2020-2027 (USD MILLION) 154

TABLE 104 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY MODE OF PURCHASE, 2020-2027 (USD MILLION) 154

TABLE 105 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY END USER, 2020-2027 (USD MILLION) 155

TABLE 106 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY SAMPLE, 2020-2027 (USD MILLION) 155

TABLE 107 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY REGION, 2020-2027 (USD MILLION) 156

6.9 URINALYSIS TESTING PRODUCTS 156

6.9.1 RISING PREVALENCE OF URINARY TRACT INFECTIONS TO DRIVE MARKET 156

TABLE 108 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY PLATFORM, 2020-2027 (USD MILLION) 157

TABLE 109 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY MODE OF PURCHASE, 2020-2027 (USD MILLION) 157

TABLE 110 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY END USER, 2020-2027 (USD MILLION) 158

TABLE 111 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY SAMPLE, 2020-2027 (USD MILLION) 158

TABLE 112 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY REGION, 2020-2027 (USD MILLION) 159

6.10 CHOLESTEROL TESTING PRODUCTS 159

6.10.1 RISING OBESITY LEVELS TO DRIVE ADOPTION OF CHOLESTEROL TESTING PRODUCTS 159

TABLE 113 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY PLATFORM, 2020-2027 (USD MILLION) 160

TABLE 114 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY MODE OF PURCHASE, 2020-2027 (USD MILLION) 160

TABLE 115 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY END USER, 2020-2027 (USD MILLION) 161

TABLE 116 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY SAMPLE, 2020-2027 (USD MILLION) 161

TABLE 117 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY REGION, 2020-2027 (USD MILLION) 162

6.11 HEMATOLOGY TESTING PRODUCTS 162

6.11.1 PREFERENCE FOR LABORATORY-BASED TESTS AMONG USERS TO IMPEDE MARKET GROWTH 162

TABLE 118 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY PLATFORM, 2020-2027 (USD MILLION) 163

TABLE 119 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY MODE OF PURCHASE, 2020-2027 (USD MILLION) 163

TABLE 120 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY END USER, 2020-2027 (USD MILLION) 164

TABLE 121 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY SAMPLE, 2020-2027 (USD MILLION) 164

TABLE 122 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY REGION, 2020-2027 (USD MILLION) 165

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

6.12 DRUGS-OF-ABUSE TESTING PRODUCTS 165

6.12.1 RISING CONSUMPTION OF ILLICIT DRUGS TO BOOST DEMAND FOR TESTING 165

TABLE 123 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY PLATFORM, 2020-2027 (USD MILLION) 166

TABLE 124 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY MODE OF PURCHASE, 2020-2027 (USD MILLION) 166

TABLE 125 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY END USER, 2020-2027 (USD MILLION) 167

TABLE 126 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY SAMPLE, 2020-2027 (USD MILLION) 167

TABLE 127 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY REGION, 2020-2027 (USD MILLION) 168

6.13 FECAL OCCULT TESTING PRODUCTS 168

6.13.1 LACK OF PROPER TRAINING FOR FECAL OCCULT TESTING TO HAMPER MARKET GROWTH 168

TABLE 128 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY PLATFORM, 2020-2027 (USD MILLION) 169

TABLE 129 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY MODE OF PURCHASE, 2020-2027 (USD MILLION) 169

TABLE 130 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY END USER, 2020-2027 (USD MILLION) 170

TABLE 131 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY SAMPLE, 2020-2027 (USD MILLION) 170

TABLE 132 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY REGION, 2020-2027 (USD MILLION) 171

6.14 THYROID-STIMULATING HORMONE (TSH) TESTING PRODUCTS 171

6.14.1 RISING CASES OF THYROID TO BOOST ADOPTION OF RAPID TESTS 171

TABLE 133 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR TSH TESTING PRODUCTS, BY PLATFORM, 2020-2027 (USD MILLION) 171

TABLE 134 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR TSH TESTING PRODUCTS, BY MODE OF PURCHASE, 2020-2027 (USD MILLION) 172

TABLE 135 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR TSH TESTING PRODUCTS, BY END USER, 2020-2027 (USD MILLION) 172

TABLE 136 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR TSH TESTING PRODUCTS, BY SAMPLE, 2020-2027 (USD MILLION) 173

TABLE 137 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR TSH TESTING PRODUCTS, BY REGION, 2020-2027 (USD MILLION) 173

6.15 OTHER PRODUCTS 173

TABLE 138 OTHER POINT-OF-CARE AND RAPID DIAGNOSTIC PRODUCTS MARKET, BY PLATFORM, 2020-2027 (USD MILLION) 174

TABLE 139 OTHER POINT-OF-CARE AND RAPID DIAGNOSTIC PRODUCTS MARKET, BY MODE OF PURCHASE, 2020-2027 (USD MILLION) 174

TABLE 140 OTHER POINT-OF-CARE AND RAPID DIAGNOSTIC PRODUCTS MARKET, BY END USER, 2020-2027 (USD MILLION) 175

TABLE 141 OTHER POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY SAMPLE, 2020-2027 (USD MILLION) 175

TABLE 142 OTHER POINT-OF-CARE AND RAPID DIAGNOSTIC PRODUCTS MARKET, BY REGION, 2020-2027 (USD MILLION) 176

7 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PLATFORM 177

7.1 INTRODUCTION 178

TABLE 143 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PLATFORM, 2020-2027 (USD MILLION) 178

7.2 LATERAL FLOW ASSAYS 178

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

7.2.1	INCREASING ADOPTION OF LFA TESTING PRODUCTS IN HOME CARE SETTINGS TO DRIVE MARKET	178
TABLE 144		
	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR LATERAL FLOW ASSAYS, BY REGION, 2020-2027 (USD MILLION)	179
7.3	IMMUNOASSAYS	179
7.3.1	RIISING INCIDENCE OF CANCER AND GROWING AWARENESS ABOUT IMMUNOASSAY PLATFORMS TO SUPPORT MARKET GROWTH	179
TABLE 145		
	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION, 2020-2027 (USD MILLION)	180
7.4	MICROFLUIDICS	180
7.4.1	EMERGING PLATFORM IN POC DIAGNOSTICS MARKET	180
TABLE 146		
	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR MICROFLUIDICS, BY REGION, 2020-2027 (USD MILLION)	181
	?	
7.5	DIPSTICKS	181
7.5.1	DIPSTICKS HELP IN ROUTINE ANALYSIS OF SEVERAL MEDICAL CONDITIONS	181
TABLE 147		
	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR DIPSTICKS, BY REGION, 2020-2027 (USD MILLION)	182
7.6	MOLECULAR DIAGNOSTICS	182
TABLE 148		
	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TECHNOLOGY, 2020-2027 (USD MILLION)	183
TABLE 149		
	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2020-2027 (USD MILLION)	183
7.6.1	RT-PCR	184
7.6.1.1	COVID-19 testing boosted demand for RT-PCR technology	184
TABLE 150		
	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR RT-PCR, BY REGION, 2020-2027 (USD MILLION)	184
7.6.2	INAAT	184
7.6.2.1	Cost benefits of INAAT to drive adoption	184
TABLE 151		
	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2020-2027 (USD MILLION)	185
7.6.3	OTHER TECHNOLOGIES	185
TABLE 152		
	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020-2027 (USD MILLION)	186
8	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY MODE OF PURCHASE	187
8.1	INTRODUCTION	188
TABLE 153		
	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2020-2027 (USD MILLION)	188
8.2	OTC TESTING PRODUCTS	188
8.2.1	RIISING FOCUS ON HOME CARE TO BOOST DEMAND FOR OTC TESTING PRODUCTS	188
TABLE 154		
	OTC POINT-OF-CARE AND RAPID TESTING PRODUCTS MARKET, BY REGION, 2020-2027 (USD MILLION)	189
8.3	PRESCRIPTION-BASED TESTING PRODUCTS	189
8.3.1	GROWING PREVALENCE OF LIFESTYLE DISEASES AND FAVORABLE REIMBURSEMENT TO DRIVE MARKET	189
TABLE 155		
	PRESCRIPTION-BASED POINT-OF-CARE AND RAPID TESTING PRODUCTS MARKET, BY REGION, 2020-2027 (USD MILLION)	190
9	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY SAMPLE	191
9.1	INTRODUCTION	192
TABLE 156		
	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY SAMPLE, 2020-2027 (USD MILLION)	192
9.2	BLOOD	192
9.2.1	RIISING APPLICATION OF BLOOD SAMPLES IN DETECTION OF VARIOUS DISEASES TO DRIVE GROWTH	192
TABLE 157		
	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY REGION, 2020-2027 (USD MILLION)	193
	?	
9.3	URINE	193
9.3.1	GROWING PREVALENCE OF KIDNEY DISORDERS TO BOOST MARKET GROWTH	193

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 158	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR URINE SAMPLES, BY REGION, 2020-2027 (USD MILLION)	194
9.4	NASAL AND OROPHARYNGEAL SWABS	194
9.4.1	INCREASING PREVALENCE OF RESPIRATORY INFECTIONS TO PROPEL MARKET GROWTH	194
TABLE 159	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR NASAL AND OROPHARYNGEAL SWABS, BY REGION, 2020-2027 (USD MILLION)	194
9.5	OTHER SAMPLES	195
TABLE 160	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY REGION, 2020-2027 (USD MILLION)	195
10	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY END USER	196
10.1	INTRODUCTION	197
TABLE 161	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY END USER, 2020-2027 (USD MILLION)	197
10.2	CLINICAL LABORATORIES	198
10.2.1	IMPROVEMENTS IN CLINICAL DIAGNOSTICS AND TESTING TECHNOLOGIES TO DRIVE MARKET	198
TABLE 162	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2020-2027 (USD MILLION)	198
10.3	AMBULATORY CARE FACILITIES AND PHYSICIANS' OFFICES	198
10.3.1	RAPID RESULT GENERATION AND AVAILABILITY OF IMMEDIATE PATIENT CARE-MAJOR FACTORS DRIVING MARKET GROWTH	198
TABLE 163	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIANS' OFFICES, BY REGION, 2020-2027 (USD MILLION)	199
10.4	PHARMACIES, RETAIL CLINICS, AND E-COMMERCE PLATFORMS	199
10.4.1	CONVENIENCE AND EASE OF EXPERT ACCESS TO DRIVE MARKET	199
TABLE 164	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PHARMACIES, RETAIL CLINICS, AND E-COMMERCE PLATFORMS, BY REGION, 2020-2027 (USD MILLION)	200
10.5	HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS	200
10.5.1	HOSPITALS LARGEST END USERS OF POC DIAGNOSTICS	200
TABLE 165	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY REGION, 2020-2027 (USD MILLION)	201
10.6	HOME CARE AND SELF-TESTING	201
10.6.1	INCREASING INCLINATION TOWARD HOME HEALTHCARE TO DRIVE MARKET	201
TABLE 166	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HOME CARE AND SELF-TESTING, BY REGION, 2020-2027 (USD MILLION)	202
10.7	OTHER END USERS	202
TABLE 167	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2020-2027 (USD MILLION)	202
11	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY REGION	203
11.1	INTRODUCTION	204
TABLE 168	POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY REGION, 2020-2027 (USD MILLION)	204

Point of Care/ Rapid Diagnostics Market by Product (Glucose, HIV, Hepatitis C, Pregnancy), Platform (Microfluidics, Dipstick, Immunoassay), Purchase(OTC, Prescription), Sample(Blood, Urine), User (Pharmacy, Hospital, Homecare) - Global Forecast to 2027

Market Report | 2022-12-08 | 383 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*

Country*

Date

Signature